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Background: The SERPINA1, SERPINA3, and SERPINE2 genes, which encode antiproteases, have been proposed to
be susceptible genes for of chronic obstructive pulmonary disease (COPD) and related phenotypes. Whether they
are associated with emphysema is not known.
Methods: Twelve previously reported single nucleotide polymorphisms (SNPs) in SERPINA1 (rs8004738, rs17751769,
rs709932, rs11832, rs1303, rs28929474, and rs17580), SERPINA3 (rs4934, rs17473, and rs1800463), and SERPINE2
(rs840088 and rs975278) were genotyped in samples obtained from 1,335 consecutive autopsies of elderly
Japanese people. The association between these SNPs and the severity of emphysema, as assessed using
macroscopic scores, was determined.
Results: Emphysema of more than moderate degree was detected in 189 subjects (14.1%) and showed a
significant gender difference (males, 20.5% and females, 7.0%; p < 0.0001). Among the 12 examined SNPs, only
rs975278 in the SERPINE2 gene was positively associated with emphysema. Unlike the major alleles, homozygous
minor alleles of rs975278 were associated with emphysema (odds ratio (OR) = 1.54; 95% confidence interval (CI) =
1.02-2.30; p = 0.037) and the association was very prominent in smokers (OR = 2.02; 95% CI = 1.29-3.15; p = 0.002).
Conclusions: SERPINE2 may be a risk factor for the development of emphysema and its association with
emphysema may be stronger in smokers.
Background
The pathogenesis of chronic obstructive pulmonary dis-
ease (COPD) involves both small airway remodeling and
emphysema [1]. Pulmonary emphysema is defined
through pathological criteria as an “abnormal permanent
enlargement of the airspaces distal to the terminal
bronchioles, accompanied by destruction of the alveolar
walls, and without obvious fibrosis” [2]. Emphysema
progression is inextricably linked to the destruction of
alveolar elastic fibers by elastolytic proteases associated
with a chronic tobacco smoke-induced inflammatory
process and to an antiprotease deficiency such as in
alpha 1- antitrypsin deficiency [3].
Cigarette smoking may induce inflammation in the
lungs and increase the release of proteases, which are
counteracted by antiproteases in order to prevent par-
enchymal injury. However, smokers in whom COPD
develops, the production of antiproteases may be inade-
quate to neutralize the effects of multiple proteases, pos-
sibly because of genetic polymorphisms that impair the
function or production of these proteins [4]. Epidemio-
logic data indicate that over 95% of patients with COPD
are current or former smokers; however, only about
10-20% of smokers develop COPD [5,6]. In this regard,
additional factors such as genetic variability contribute
to smoke susceptibility [7].
Serpins constitute a group of protease inhibitors com-
prising 36 human proteins [8]. Serpins regulate processes
such as coagulation and inflammation by blocking targets
of chymotrypsin-like serine proteases such as thrombin,
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lished nomenclature for serpins [9], the human genome
encodes 16 clades of serpins–Serpin A through Serpin
P–and the corresponding genes are further categorized
into 29 inhibitory and 7 non-inhibitory genes [10]. SER-
PINA1, SERPINA3,a n dSERPINE2 are reported to be
associated with COPD [11-22].
Alpha 1-antitrypsin deficiency is a high risk factor for
COPD [11,12] and is associated with rare polymorph-
isms in the SERPINA1 gene. In fact, studies on common
SERPINA1 variants have revealed that SERPINA1 haplo-
types are associated with COPD [13], albeit not very
conspicuously.
Alpha 1-antichymotrypsin, encoded by SERPINA3,i sa
plasma protease inhibitor that targets neutrophil cathe-
psin G and elastase [14]. In several cases, mutations in
SERPINA3 are found to be associated with COPD [15].
A similar but less prominent association is found
between COPD and common variants of SERPINA3
[16-18].
SERPINE2 encodes protease nexin 1–the archetypal
member of the serine protease inhibitor family. DeMeo
and associates first suggested that SERPINE2 is a COPD
susceptibility gene and is probably influenced by a gene-
by-smoking interaction in the Boston Early-Onset
COPD study [19]. Subsequently, this was further vali-
dated and supported by additional data [20-22].
Although a number of large population studies are
reported for COPD, few studies are well reproduced,
probably due to the heterogenous mixture of COPD
phenotypes. As COPD is composed of at least two com-
ponents, the examination of emphysema might reduce
the heterogeneity, and provide insight into specific
mechanisms associated with mortality. In this study, we
investigated 12 putative causal SNPs in SERPINA1, SER-
PINA3,a n dSERPINE2 by using autopsy samples
obtained from 1,335 consecutive Japanese individuals.
We then studied the association between these SNPs




From February, 1995 to July, 2003, 1,536 autopsies were
performed at the Department of Pathology, Tokyo
Metropolitan Geriatric Medical Center, Tokyo, Japan. Of
these, 1,335 (717 males and 618 females) were performed
on Japanese cadavers, and the pathological findings of
the lungs obtained during these autopsies were used in
this study. The characteristics of the study population are
available at an Internet-based database called “The
Japanese SNP database for geriatric research (JG-SNP)”
http://www.tmghig.jp/jg-snp/english/E_top.html.
Smoking status of the individuals was retrospectively
determined by reviewing medical records, and subjects
were classified as smokers (including ex-smokers) and
life-time never-smokers. No medico-legal cases were
included in the study. We did not use data from lung-
function tests for association analysis because limited
data were available, and because the duration between
the conduction of these tests and death varied widely.
Pathological assessment of emphysema
Both excised lungs were inflated with a 10% formalin
solution at a constant pressure of 25 cm H2O. The
lungs were section in the sagittal plane to obtained
2-cm-thick slices.
The type and severity of the emphysematous changes
in all the lung slices were macroscopically assessed by a
pulmonary pathologist (K.T.). Emphysema was classified
as centrilobular emphysema (CE), panlobular emphy-
sema (PE), or focal emphysema (FE), and its severity
was scored on a scale of 0-4 for each slice, by using a
previously described method [2,23], where 0 = no
changes, 1 = minimal changes, 2 = mild changes, 3 =
moderate changes, and 4 = severe changes. The mean
scores for slices from both lungs were used in an asso-
ciation analysis of single nucleotide polymorphisms
(SNPs) (see below). In this study, emphysema was
defined as CE changes with a score of >2 and/or PE
changes with a score of ≥ 1, since CE changes are
k n o w nt ob em a i n l yc a u s e db ys m o k i n g ,a n dP Ew i t h
CE is considered an extension of severe CE [24].
Patients whose emphysema scores for both lungs dif-
fered by more than 2 points were excluded from the
study, because in general, the bilateral severity of the
emphysema is closely correlated [24], and such wide dif-
ferences might have been due to additional unusual
effects.
SNP selection
We selected 7 SERPINA1 SNPs (rs8004738, rs17751769,
rs709932, rs11832, rs1303, rs28929474, and rs17580), 3
SERPINA3 SNPs (rs4934, rs17473, and rs1800463), and 2
SERPINE2 SNPs (rs840088 and rs975278) by referring to
previous studies on COPD phenotypes [13,15,16,19,20].
The SNPs whose minor allele frequencies (MAFs) in the
Japanese population were found to be less than 0.1 in the
HapMap project http://hapmap.ncbi.nlm.nih.gov/ were
excluded from this study. One of the SERPINE2 SNPs
(rs840088; intron 1) has been reported to be associated
with COPD in both family and case-control studies [19],
and the other (rs975278; intron 5) has been reported to
be associated with COPD phenotypes in 2 large popula-
tions [20]. We also screened for the PiS variant (rs17580)
and PiZ variant (rs28929474), which are known to be the
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deficiency [25,26].
Genotyping
Genomic DNA was extracted from the renal cortex by
the phenol-chloroform method and stored at -20°C until
use. For genotype analysis, 10-ng aliquots of DNA were
introduced into 384-well polymerase chain reaction
(PCR) plates by using an automated fluid dispenser (Bio-
Mek2000; Beckman Coulter Inc., Fullerton, CA) and
dried in a dry chamber.
Two SERPINE2 SNPs (rs840088 and rs975278) and
one SERPINA1 SNP (rs1303) were genotyped using Taq-
man 5’-exonuclease assays, with primers obtained from
Applied Biosystems Inc. (Foster City, CA). Major and
minor allele probes were labeled with different colored
fluorophores, and the fluorescence signals were detected
using the ABI Prism 7900HT sequence detector system.
The remaining 9 SNPs were genotyped using a melting
curve analysis on a LightCycler 480 system (Roche Diag-
nostics K. K., Tokyo, Japan). Pathological assessments
and genotyping were performed at different facilities in
a double-blind manner. The PCR primers and hybridiza-
tion probes used for the melting curve analysis are listed
in additional file 1, table S1.
Ethical considerations
All the autopsies and subsequent medical and genetic
studies were performed with the written informed con-
sent of the bereaved family of each patient. The use of
autopsy materials for medical education and research is
generally permitted by the Act of Postmortem Examina-
tions of Japan. This study was approved by the ethics
committees of Tokyo Metropolitan Geriatric Medical
Center and Tokyo Medical and Dental University.
Statistical analysis
Allelic test and genotype test in recessive model were
used to detect the genetic contributions. Statistical ana-
lysis was performed using SAS ver. 9.1.3 (SAS Institute
Inc., Cary, NC). Multiple logistic regression analyses
were performed to examine the emphysema-related dif-
ferences in the patients’ clinical backgrounds and to cal-
culate the odds ratio (ORs) and 95% confidence
intervals (CIs). The estimates were adjusted for gender,
age at the time of death, and smoking status. The
Hardy-Weinberg equilibrium for all SNPs was tested
using the chi-square goodness-of-fit test. Haplotype ana-
lyses of 5 SNPs (rs8004738, rs17751769, rs709932,
rs11832, and rs1303) were performed using the stochas-
tic expectation-maximization (EM) algorithm, which is
incorporated in the THESIAS program http://ecgene.
net/genecanvas/uploads/THESIAS3.1/Documentation3.1.
htm. A p value of < 0.05 was considered statistically




The baseline characteristics of the subjects are shown in
Table 1. The mean age at the time of death was 80.1
years. Of the 1355 subjects, 99 (7.4%) had CE with mini-
mal changes, 248 (18.6%) had mild changes, 156 patients
(11.7%) had moderate changes, 28 patients (2.1%) had
severe changes, and the remaining 804 patients (60.2%)
had no detectable emphysema. The pathological diagno-
sis of emphysema, which was defined as previously
described, was made on 14.2% of the subjects (n = 189).
Emphysema was more common among men than
among women (20.5% vs. 7%; p < 0.0001). Further,
47.1% of the study population had a history of smoking,
with a significant gender difference (males vs. females;
69.6% vs. 21.0%; p < 0.0001). Smoking was found to be
a significant risk factor for the development of emphy-
sema in the total study population (OR = 4.45, 95%
CI = 2.88-7.06; p < 0.0001), and posed a slightly higher
risk in women (OR = 5.22, 95% CI = 2.59-10.70; p <
0.0001) than in men (OR = 4.14, 95% CI = 2.40-7.65;
p < 0.0001).
Association between genetic polymorphisms of candidate
genes and emphysema
The distribution of the 12 SNP genotypes and their asso-
ciation with emphysema are shown in Table 2. Neither
the PiZ and PiS variants (rs28929474 and rs17580 respec-
tively) nor the 2 reportedly rare variants of SERPINA3
(rs17473 and rs1800463) were detected in any of the
samples examined. The MAFs obtained in our analysis
did not considerably deviate from the data obtained in
the HapMap project http://hapmap.ncbi.nlm.nih.gov/.
The distribution of all genotypes did not significantly
deviate from the Hardy-Weinberg equilibrium.
Subjects with and without emphysema did not show
any differences in the genotypic distribution of 5 SER-
PINA1 SNPs and 1 SERPINA3 SNP. However, significant
differences were found in the genotypic distribution of 1
SERPINE2 SNP (rs975278). This SNP was significantly
associated with emphysema (OR = 1.54, 95% CI = 1.02-
2.30; p = 0.037)
Association of the SERPINE2 SNP rs975278 and smoking
with emphysema
We next examined whether the effects of rs975278 dif-
fered between smokers and non-smokers. Among the
smokers, the allelic and genotypic frequencies of this
SNP were significantly different between subjects with
and without emphysema (Table 3). A high frequency of
GG homozygosity was significantly associated with an
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1.29-3.15; p = 0.002).
We performed haplotype analyses for 5 adjacent SER-
PINA1 SNPs, but none of the haplotypes was found to
be associated with emphysema (data not shown).
Discussion
The present study revealed that a polymorphism in SER-
PINE2 (rs975278) was associated with emphysema in
consecutive autopsies of Japanese subjects. In the total
study population, the OR for minor allele homozygotes
was 1.54 (95% CI = 1.02-2.30). Among smokers, the OR
for minor allele homozygotes was 2.02 (95% CI = 1.29-
3.15). If the p values are corrected with multiple testing
of twelve SNPs, the data without smoking stratification
does not show any statistical significance. Among the
smokers, however, the differences of the allelic and gen-
otypic frequencies between subjects with and without
emphysema were significant (p value × 12 < 0.05). To
our knowledge, this is the first study to report that a
SERPINE2 variant is closely associated with emphysema,
especially in smokers.
SERPINE2
SERPINE2 encodes a 44-kDa cellular and extracellular
matrix-associated serine protease inhibitor [27], which is
expressed in the developing and adult lung as well as in
the airway epithelial cells [19]. The SERPINE2 protein
mainly functions in coagulation and fibrinolysis by inhi-
biting thrombin, urokinase, and plasmin [27,28]. Plasmin
is capable of contributing to metalloproteinase activation
[29], thus, SERPINE2 may play an important role in lung
physiology [30].
SERPINE2 was initially identified as a positional candi-
date for COPD and related phenotypes on chromosome
2q33-35 [31]. Subsequently the association of SNPs in
SERPINE2 with COPD was observed in a case-control
study in smokers [19]. Three independent groups
attempted to replicate the findings of the above study:
one study successfully replicated the association [20],
Table 1 Clinical characteristics of the cases
Total (%)
N = 1335
Subjects with emphysema (%)
N = 189
Subjects without emphysema (%)
N = 1146
p values
Men (%) 717 (53.7%) 147 (77.8%) 570 (49.7%) <0.0001*
Age (years) 80.1 ± 9.0 81.3 ± 7.3 79.9 ± 9.3 <0.0001
†
History of smoking
Smokers 629 (47.1%) 146 (77.2%) 483 (42.1%) <0.0001
‡
Non-smokers 610 (45.7%) 32 (16.9%) 578 (50.4%)
Data not available 96 (7.2%) 11 (5.8%) 85 (7.4%)
Pack-years 21.2 ± 36.3 45.0 ± 40.5 17.7 ± 31.9 <0.0001
‡
*Multiple logistic regression analysis adjusted for age and smoking history.
†Multiple logistic regression analysis adjusted for sex and smoking history.
‡Multiple logistic regression analysis adjusted for age and sex.
Table 2 Association of 12 SNPs with emphysema


















rs8004738 A/G .26/.50/.24 .24/.51/.25 .873 .761 .459
rs17751769 A/G .26/.50/.24 .24/.50/.26 .858 .902 .573
rs709932 G/A .53/.40/.07 .56/.37/.07 .450 .439 .866
rs1303 A/C .47/.42/.11 .51/.40/.09 .896 .275 .572
rs11832 A/G .45/.42/.13 .49/.40/.11 .148 .217 .416
SERPINA3
rs4934 A/G .37/.44/.19 .35/.47/.18 .440 .699 .910
SERPINE2
rs840088 C/T .32/.49/.19 .35/.48/.17 .928 .699 .908
rs975278 A/G .26/.47/.27 .29/.52/.19 .329 .175 .037
*Multiple logistic regression analysis adjusted for age, sex, and smoking history.
Statistically significant values (p < 0.05) are shown in boldface.
p values shown above have not been adjusted for multiple testing.
Abbreviations: MM, major allele homozygote; Mm, heterozygote; mm, minor allele homozygote; HWE, Hardy-Weinberg equilibrium.
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polymorphisms were used to study COPD-related phe-
notypes; association with hypoxemia with severe COPD
[34] and with bronchodilator responsiveness in COPD
[35] were observed. Thus, accumulating evidence shows
that SERPINE2 i sas u s c e p t i b l eg e n eo fC O P Da n da
modifier of COPD related phenotypes, but its relation
with emphysema remains unknown. Our finding that
SERPINE2 polymorphism is associated with emphysema
appears to be consistent with the findings of these pre-
vious studies that reported positive associations [19,20],
as assessed using physiological parameters of lung func-
tion. According to the Hapmap project, the allele fre-
quencies of the polymorphism (rs975278) are different
in population groups, however, the risk allele (G allele)
pointed to the same direction in the present study.
These previous findings were further explored in our
study, which analyzed pathological findings in consecu-
tive autopsy cases.
In this study, the association of SERPINE2 polymorph-
ism with emphysema was more prominent among the
smokers. This suggests that SERPINE2 variants contri-
bute to the risk of developing emphysema in smokers.
While the reason for this interaction is presently
unclear, many smoking-associated genes have been iden-
tified [36]. It is tempting to speculate that SERPINE2
polymorphism may affect SERPIMI2 expression after
exposure to cigarette smoke and may thus hamper the
repair of smoking-induced lung damage. However,
the mechanism by which SERPINE2 contributes to the
development of emphysema remains to be elucidated.
We also examined whether the variants studied were
associated with the typical complications related to
COPD, including osteoporosis, aortic aneurysm, myocar-
dial infarction, aortic dissection, cerebral infarction,
intracranial hemorrhage, and interstitial pneumonitis.
Our results in this regard were negative (data not shown).
Emphysema and COPD
COPD is a clinical condition that is diagnosed by physio-
logical tests, whereas pulmonary emphysema is diagnosed
by pathological examinations. Although these conditions
are not identical, both are indicative of a disease invol-
ving airway obstruction and chronic bronchitis. An
important feature of our study is that we performed
pathological examinations to evaluate the disease pheno-
type; such analysis is usually not possible in routine clini-
cal practice. The genetic contribution we investigated for
emphysema may be more reflecting the final steps of the
COPD that involve severe alveolar damage due to imbal-
ance of proteaseses and their inhibitors.
With the recent advancements in computed tomogra-
phy (CT), high-resolution images that enable a reason-
ably accurate assessment of pulmonary emphysema can
be obtained [37]. Emphysema appears to be correlated
with the severity of lung function impairment in COPD
[38]; however, attempts have been made to categorize
COPD, regardless of whether emphysema is detected
using CT. Some candidate gene polymorphisms are
reported to be associated with emphysema, as diagnosed
using CT [39-41]. We believe that SERPINE2 is a good
candidate gene that is associated with emphysema, as
diagnosed using CT.
Thus, our finding that a SERPINE2 variant is asso-
ciated with emphysema may indicate that this variant
influences the severity of lung destruction rather than
the presence or absence of chronic pulmonary obstruc-
tion. Future studies should aim to elucidate the genetic
background of COPD with and without pulmonary
emphysema.
Limitations
S p i r o m e t r i cd a t aw e r en o ts u f f i c i e n t l ya v a i l a b l ei nt h i s
study since the samples were obtained during autopsies
of elderly subjects. Small number of subjects, especially
only 32 non-smoker patients have pulmonary emphy-
sema, may reduce power to detect genetic associations.
The present study included only those individuals who
underwent autopsy and had an average age with emphy-
sema was similar to those without emphysema (Table 1).
This implies that the study population may have been
skewed towards individuals with mild disease, and that a
Table 3 Association of rs975278 with emphysema in smokers




p value* Odds ratio (95%)*
Genotype
GG 42 (33%) 83 (20%) .002 2.02 (1.29-3.15)
AG+AA 85 (67%) 342 (80%)
Allele
G 0.57 0.45 .001 2.61 (1.45-4.76)
A 0.43 0.55
*Multiple logistic regression analysis adjusted for age and sex.
Statistically significant figures (p < 0.05) are shown in boldface.
p values shown above have not been adjusted for multiple testing.
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tion is likely to be exposed to long-term environmental
effects other than smoking; however, the present study
did not consider these effects.
Conclusions
The present study revealed that a SERPINE2 SNP
(rs975278) was associated with pathologically diagnosed
emphysema in consecutive autopsies of Japanese smo-
kers. Further studies are required to clarify the molecular
and biochemical mechanisms underlying this association.
Additional material
Additional table S1: Primers and probes used for genotyping.T h e
PCR primers and hybridization probes used for the melting curve
analysis.
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